The Mid-term Survival of Robotic Lobectomy Resection of Non-Small Cell Lung Cancer (NSCLC): A Multi-Institutional Study
*Robert J Cerfolio1, Asem F Ghanim1, Mark Dylewski2, Giulia Veronesi3, Lorenzo Spaggiari4, Bernard J Park5
1UAB, Birmingham, AL;2Baptist Health of South Florida, South Miami, FL;3Istituto Clinico Humanitas Cancer Center, Istituto Europeo Di Oncologia, Milan, Italy4Istituto Europeo Di Oncologia, Milan, Italy5Memorial Sloan Kettering Cancer Center, New York, NY
BACKGROUND - Our objective is to report the world's largest series with the longest follow-up of robotic lobectomy for non-small cell lung cancer (NSCLC).
METHODS - This is a multi-institutional review of a consecutive series of patients from four institutions' prospective robotic databases.
RESULTS - There were 1,339 patients (men 55%, median age 68). The median operative time was 136 minutes, median number of lymph nodes was 13 (5 N2 stations and 1 N1), median blood loss was 50 cc (4 0.005%, received intra-operative transfusions). Conversions occurred in 113 patients (8%) and for bleeding in 21 (2%). Median length of stay was 3 days. Major morbidity occurred in 8%. The 30-day and 90-day operative mortality was 0.2% and 0.5%, respectively. Follow-up was complete in 99% with a median follow up of 28 months (range 1 -154 months). The 5-year stage-specific survival was: 83% for the 672 patients with stage IA NSCLC, 77% for the 281 patients with stage IB, 68% for the 118 patients with stage IIA, 70% for 99 patients with IIB, 62% for 143 patients with stage IIIA (122 had N2 disease, 73%) and 31% for 8 patients with stage IIIB (none had N3 disease). The 5 -year survival curve is shown below. Recurrent NSCLC occurred in 128 patients (11%) local recurrence in the ipsilateral operated chest occurred in only 2%.
CONCLUSIONS - The mid-term oncologic results of robotic lobectomy for non-small cell lung cancer are promising especially for patients with pathologic N2 disease. Further studies are needed.
Back to 2017 Program